That nicotine addiction sustains tobacco use for most smokers is well established. Once a person is addicted to nicotine, quitting smoking is difficult, and more than 90 percent of smokers who try to quit each year fail. It follows that an important component of a policy to reduce tobacco use in the population is to prevent development of nicotine addiction in young people. Young people do not start to smoke because they are addicted, but once they begin to smoke become addicted, which sustains smoking into adulthood. It is difficult to prevent adolescents from experimenting with cigarettes; however, by reducing the content of nicotine in tobacco products, it may be possible to prevent the transition from experimental smoking to addiction. The Food and Drug Administration has gained jurisdiction to regulate nicotine, but FDA does not know yet how best to do it. One of the most widely discussed proposals is a gradual reduction of the nicotine content of all cigarettes to a level that does not sustain nicotine addiction. Such a cigarette could prevent adolescents from becoming addicted, and might also serve to wean adult smokers to a lower level of addiction and, therefore, facilitate quitting. Of concern with such a policy is whether compensatory oversmoking of cigarettes will be harmful to already addicted smokers. This proposal aims to examine the safety of reducing the nicotine content of cigarettes gradually. Volunteer smokers will smoke research cigarettes with progressively reduced nicotine contents over three or six months, with concomitant assessment of exposure to tobacco smoke nicotine, gas and tar, using the biomarkers of blood and urinary cotinine, urinary nicotine and metabolites, carboxyhemoglobin, urinary mutagenicity, urine solanesol, as well as measurement of cigarette puffing behavior. To examine the importance of the rate of nicotine reduction, measurements will be made in smokers in conditions where nicotine content is tapered over 12 weeks compared to over 24 weeks. The proposed research is needed to guide the FDA as how best to regulate nicotine in cigarettes and is an essential first step in examining the feasibility of a national nicotine regulation program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078603-04
Application #
6513301
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Djordjevic, Mirjana V
Project Start
1999-06-01
Project End
2004-08-31
Budget Start
2002-04-01
Budget End
2004-08-31
Support Year
4
Fiscal Year
2002
Total Cost
$585,563
Indirect Cost
Name
University of California San Francisco
Department
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Nardone, Natalie; Donny, Eric C; Hatsukami, Dorothy K et al. (2016) Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. Addiction 111:2208-2216
Benowitz, Neal L; Nardone, Natalie; Hatsukami, Dorothy K et al. (2015) Biochemical estimation of noncompliance with smoking of very low nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev 24:331-5
Bandiera, Frank C; Ross, Kathryn C; Taghavi, Seyedehtaraneh et al. (2015) Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. Nicotine Tob Res 17:1167-72
Benowitz, Neal L; Nardone, Natalie; Dains, Katherine M et al. (2015) Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up. Addiction 110:1667-75
Calfee, Carolyn S; Matthay, Michael A; Kangelaris, Kirsten N et al. (2015) Cigarette Smoke Exposure and the Acute Respiratory Distress Syndrome. Crit Care Med 43:1790-7
Hatsukami, Dorothy K; Donny, Eric C; Koopmeiners, Joseph S et al. (2015) Compensatory smoking from gradual and immediate reduction in cigarette nicotine content. Cancer Epidemiol Biomarkers Prev 24:472-6
Zhu, Andy Z X; Zhou, Qian; Cox, Lisa Sanderson et al. (2014) Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos 42:1971-7
St Helen, Gideon; Dempsey, Delia; Wilson, Margaret et al. (2013) Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. Addiction 108:607-17
Benowitz, Neal L; Henningfield, Jack E (2013) Reducing the nicotine content to make cigarettes less addictive. Tob Control 22 Suppl 1:i14-7
Benowitz, Neal L; Zhu, Andy Z X; Tyndale, Rachel F et al. (2013) Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenet Genomics 23:135-41

Showing the most recent 10 out of 28 publications